Drugs
Donald W. Grimm, a veteran executive from the pharmaceutical, biotechnology, and medical device industries, has joined Qualigen's Board of Directors. With a distinguished career spanning over three decades, Grimm brings a wealth of expertise to the company. His most notable achievements include leading Hybritech, Inc. to a significant
Pharmaceutical industry
Aventis, a leading European drug company, has signed a massive $450 million deal with biotechnology start-up Millennium Pharmaceuticals, Inc. as part of a comprehensive alliance to develop and commercialize new drugs. Under the agreement, Aventis will acquire a 2% stake in Millennium by purchasing $250 million worth of shares, with
Pharmaceutical industry
Aventis Pharma and Millennium Pharmaceuticals have announced a landmark partnership that will revolutionize the field of inflammatory diseases. The collaboration, which combines Aventis' expertise in pharmaceuticals with Millennium's cutting-edge biotech capabilities, aims to discover and develop innovative treatments for conditions such as rheumatoid arthritis, asthma, and multiple
Drugs
Tamiflu, the number one prescribed antiviral treatment for influenza, has been shown to effectively treat children aged 1 year and older for acute influenza, a significant medical breakthrough considering the high incidence of the disease in this age group. The new indication was supported by clinical trial data demonstrating a
Drugs
Medarex and MedImmune announced a partnership to develop fully human antibodies using Medarex's HuMAb-Mouse technology. Under the agreement, MedImmune gains exclusive rights to the technology for the development of antibodies against respiratory syncytial virus (RSV) and an option to further license the technology for additional antigens. Medarex will
Drugs
The Nasdaq Biotechnology Index saw a significant surge of over 6% on Friday, driven by the performance of top biotech companies such as Sepracor, Transkaryotic Therapeutics, and Ribozyme Pharmaceuticals. These companies were among the 15 presenting at the Boston Biotechnology Forum, held at the Seaport Hotel and online at informedinvestors.
Drugs
Genta Incorporated, a biopharmaceutical company specializing in anticancer therapy, has partnered with Molecular Biosystems Inc. to license a comprehensive portfolio of patents and technology related to antisense therapeutic and diagnostic applications. The agreement grants Genta exclusive and non-exclusive rights to the technology, allowing the company to expand its intellectual property
Drugs
Chesapeake Biological Laboratories, Inc., a Baltimore-based pharmaceutical and medical device developer, has announced that one of its clients has received FDA approval for commercial manufacturing. Additionally, a second client has received a FDA approvable letter, signifying the final step before FDA clearance for marketing in the United States. The third
Drugs
The US FDA has released several updates to its regulations and guidance documents in recent months, covering various areas including over-the-counter human drugs, biologics, and medical devices. The updates aim to improve compliance, enhance safety, and provide clarity to industry stakeholders. The Federal Register, a government publication, lists the issue
Drugs
Paradigm Medical Industries, Inc. and Pharmacia Corporation announced the renewal of their strategic alliance contract at the recent annual meeting of the American Society of Cataract and Refractive Surgeons (ASCRS) in Boston, Massachusetts. The contract strengthens their competitive position in the ophthalmic cataract surgical market, with Paradigm supplying surgical equipment
Drugs
Preliminary results from a Phase II study indicate that AROMASIN (exemestane tablets) may extend the time postmenopausal women with advanced breast cancer remain free of tumor growth when compared to tamoxifen, currently the standard hormonal therapy for first-line treatment. The study, conducted by the European Organization for Research and Treatment
Drugs
AstraZeneca, the world's largest seller of a single drug, is being investigated by the European Commission over allegations that it has broken competition rules in defending the patents on its best-selling ulcer treatment, Losec. The investigation came after the Commission raided the company's London and Swedish
